Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Melis M, Trasino SE, Tang X-, Rappa A, Zhang T, Qin L, et al. Retinoic Acid Receptor β Loss in Hepatocytes Increases Steatosis and Elevates the Integrated Stress Response in Alcohol-Associated Liver Disease. Int J Mol Sci. 2023;24(15).

Pederzoli F, Raffo M, Pakula H, Ravera F, Nuzzo PV, Loda M. "Stromal cells in prostate cancer pathobiology: friends or foes?". Br J Cancer. 2023;128(6):930-939.

Nassar AH, Alaiwi SA, Baca SC, Adib E, Corona RI, Seo J-, et al. Epigenomic charting and functional annotation of risk loci in renal cell carcinoma. Nat Commun. 2023;14(1):346.

Magro CM, Kalomeris TA, Mo JH, Rice M, Nuovo G. Lichen sclerosus: A C5B-9 mediated chronic microvascular injury syndrome potentially reflective of common adult comorbidities. Ann Diagn Pathol. 2023;63:152098.

Bakht MK, Yamada Y, Ku S-, Venkadakrishnan VB, Korsen JA, Kalidindi TM, et al. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat Cancer. 2023;4(5):699-715.

Hissong E, Zhao L, Shi J. Clinicopathologic and Molecular Features of Pancreatic Ductal Adenocarcinomas Harboring Alterations in COMPASS-like Complex Genes. Arch Pathol Lab Med. 2023;147(9):1050-1059.

Vidotto T, Imada EL, Faisal F, Murali S, Mendes AA, Kaur H, et al. Association of self-identified race and genetic ancestry with the immunogenomic landscape of primary prostate cancer. JCI Insight. 2023;8(3).

Zhang T, Li S, Tan YA, Na JH, Chen Z, Damle P, et al. Bcl-xL is translocated to the nucleus via CtBP2 to epigenetically promote metastasis. bioRxiv. 2023.

Callum J, Bégin P, Jamula E, Liu Y, Kron AT, Auclair M-, et al. Lessons learned from the CONCOR-1 trial. Transfus Med. 2023;33(1):21-25.

Rubinstein PG, Moore PC, Bimali M, Lee JY, Rudek MA, Chadburn A, et al. Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial. Lancet Haematol. 2023;10(8):e624-e632.